Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma | Future Oncology
PharmaWiki - Regorafenib
Regorafenib | C21H15ClF4N4O3 | CID 11167602 - PubChem
Regorafenib: Uses, Interactions, Mechanism of Action | DrugBank Online
Regorafenib 755037-03-7 wiki
JPM | Free Full-Text | Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase
Lestaurtinib, JAK2, FLT3 and TrkA receptor tyrosine kinase inhibitor (ab142107) is not available
Regorafenib | C21H15ClF4N4O3 | ChemSpider
Regorafenib | C21H15ClF4N4O3 | CID 11167602 - PubChem
Regorafenib metabolite M4 | C20H13ClF4N4O3 | CID 53491672 - PubChem
Regorafenib | C21H15ClF4N4O3 | CID 11167602 - PubChem
New Drug Approvals 2012 - Pt. XXI - Regorafenib (Stivarga®)
REGORAFENIB ANHYDROUS
Regorafenib | C21H15ClF4N4O3 | CID 11167602 - PubChem
JPM | Free Full-Text | Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase
Regorafenib | C21H15ClF4N4O3 | CID 11167602 - PubChem
Regorafenib 755037-03-7 wiki
File:Systemic targeted therapy options for intermediate and advanced HCC.png - Wikimedia Commons
Deciphera gets Health Canada authorisation for Qinlock to treat GIST
